Bayer says FDA rejects wider use of Xarelto drug
FRANKFURT Feb 14 (Reuters) - U.S. health regulators have declined to approve a proposed wider use of Bayer and Johnson & Johnson's anti-clotting drug Xarelto, Bayer said on Friday.
The companies had sought approval by the U.S. Food and Drug Administration (FDA) to widen the use of the oral drug to also reduce the risk of thrombotic cardiovascular events and stent thrombosis in patients with Acute Coronary Syndrome (ACS).
So far, Xarelto is mainly given to prevent strokes in the elderly, among other approved uses.
An advisory panel to the FDA concluded in January that Xarelto should not be cleared for the extended use.
- Exclusive: Angry with Washington, 1 in 4 Americans open to secession
- Scots spurn independence in historic vote, devolution battle begins |
- Eight bodies found after attack on Guinea Ebola education team
- Alibaba surges 38 percent on massive demand in market debut |
- Special Report: Scotland stays in UK, but Britain faces change